Who to call at Neurocrine Biosciences, Inc., and when
Fundz watches for the moments Neurocrine Biosciences, Inc. starts buying, and tells you who to reach.
- An alert the day Neurocrine Biosciences, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Neurocrine Biosciences, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Neurocrine Biosciences, Inc.. With Fundz connected, it knows.
Neurocrine Biosciences, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
www.neurocrine.comAI Executive Summary
AI-powered analysis of 8-K filing content
Neurocrine Biosciences amended the employment agreement of former Chief Medical Officer Eiry W. Roberts, M.D., extending her Strategic Advisor role through December 31, 2026. The change formalizes a leadership transition that took effect June 2, 2025, when Sanjay Keswani, M.D. succeeded her as CMO.
Key Takeaways
Dr. Eiry W. Roberts' Strategic Advisor term was extended by 12 months, from December 31, 2025 to December 31, 2026, under an amendment signed November 21, 2025.
The extension follows Dr. Roberts' June 2, 2025 transition from Chief Medical Officer to advisory role, with Sanjay Keswani, M.D. succeeding her as CMO.
2 more takeaways
Related Filings (4)
4 more filings from Neurocrine Biosciences, Inc. in the last 90 days
Filing Overview
What This Means
Neurocrine Biosciences, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.